Aleksandra Rachitskaya, MD; Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD
Show Description +
As retina inches closer to a therapy that is safe and effective for the treatment of GA in the presence of dry AMD, the VBS Journal Club meets to review a pair of papers on two pipeline treatments undergoing phase 3 evaluations. Aleksandra Rachitskaya, MD, is joined by Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD, to review phase 2/3 GATHER1 study, which is evaluating the safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio). They also discuss a post hoc evaluation of the phase 2 FILLY study to determine which factors may be linked to the development of exudative AMD in some study patients after treatment with pegcetacoplan (Apellis).
Posted: 9/17/2021
Aleksandra Rachitskaya, MD; Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD
As retina inches closer to a therapy that is safe and effective for the treatment of GA in the presence of dry AMD, the VBS Journal Club meets to review a pair of papers on two pipeline treatments undergoing phase 3 evaluations. Aleksandra Rachitskaya, MD, is joined by Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD, to review phase 2/3 GATHER1 study, which is evaluating the safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio). They also discuss a post hoc evaluation of the phase 2 FILLY study to determine which factors may be linked to the development of exudative AMD in some study patients after treatment with pegcetacoplan (Apellis).
Posted: 9/17/2021
New Retina Radio is forging forward with education, and they’re partnering with Vit Buckle Society to make it happen. Check out these quick-hit reviews of journal articles delivered by VBS members.
New Retina Radio Journal Club: Exudative AMD in FILLY and GATHER1 Results
Aleksandra Rachitskaya, MD; Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD
Please log in to leave a comment.